SCHEMBL4701313

SCHEMBL4701313

CC/C(=N/N)c1cccc(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
PARP1 P09874 1/20 0.53
PRSS1 P07477 1/20 0.53
PRSS2 P07478 1/20 0.53
PRSS3 P35030 1/20 0.53
CES2 O00748 1/20 0.51
CES1 P23141 1/20 0.51
STS P08842 2/20 0.48
KCNK3 O14649 2/20 0.47
KCNK9 Q9NPC2 2/20 0.47
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
HSD11B1 P28845 1/20 0.44
MTNR1B P49286 1/20 0.44
HTR3E A5X5Y0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701315 1.00 NPC1 (0.53) NPC1RAB9APARP1PRSS1PRSS2
SCHEMBL15164585 0.85 GAA (0.58) NPC1RAB9APARP1PRSS1PRSS2
SCHEMBL4704407 0.77 C1S (0.48) NPC1RAB9APARP1SMN1; SMN2GAA
SCHEMBL4704405 0.77 C1S (0.48) NPC1RAB9APARP1SMN1; SMN2GAA
SCHEMBL13370034 0.77 MEN1 (0.45) NPC1RAB9APRSS1PRSS2PRSS3
SCHEMBL28839880 0.77 NPC1 (0.73) NPC1RAB9APARP1PRSS1PRSS2
SCHEMBL31309840 0.77 NPC1 (0.73) NPC1RAB9APARP1PRSS1PRSS2
SCHEMBL20040141 0.75 NPC1 (0.51) NPC1RAB9APARP1PRSS1PRSS2
SCHEMBL25455101 0.75 NPC1 (0.54) NPC1RAB9APARP1PRSS1PRSS2
SCHEMBL22193568 0.75 NPC1 (0.54) NPC1RAB9APARP1PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440059-B1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2008-04-16 EP disclosed
US-20070054950-A1 3-Azabicyclo[3.1.0]hexane derivatives PFIZER INC. 2007-03-08 US disclosed
US-7049335-B2 3-azabicyclo[3.1.0]hexane derivatives PFIZER INC. (US) 2006-05-23 US disclosed
US-20050171178-A1 3-Azabicyclo[3.1.0]hexane derivatives PFIZER INC 2005-08-04 US disclosed
EP-1440059-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS Pfizer Products Inc. (US) 2004-07-28 EP disclosed
US-20030087898-A1 3-azabicyclo[3.1.0]hexane derivatives PFIZER INC. 2003-05-08 US disclosed
WO-2003035622-A1 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087898-A1 3-azabicyclo[3.1.0]hexane derivatives OPRD1, OPRM1, OPRK1 NPC1 1974/4885RAB9A 596/4885PARP1 1416/4885
US-20050171178-A1 3-Azabicyclo[3.1.0]hexane derivatives OPRD1, OPRM1, OPRK1 NPC1 2212/4885RAB9A 552/4885PARP1 1732/4885
US-20070054950-A1 3-Azabicyclo[3.1.0]hexane derivatives OPRD1, OPRM1, OPRK1 NPC1 2197/4885RAB9A 462/4885PARP1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.